The Latin America, Middle East and Africa Atopic Dermatitis Drugs Market would witness market growth of 11.4% CAGR during the forecast period (2022-2028).
Many AD patients do get better with time. Patients with AD may also experience allergic rhinitis & asthma, which may not get better at the same time. The illness lasts for decades in the majority of cases of AD in childhood start. Relapses and remissions of the illness are common, and medication is frequently needed to prevent relapses.
People who are exposed to smoking, tobacco, pollen, detergent, pet dander, fumes, soap, and wool on a regular basis will experience ongoing symptoms, and their general quality of life will be poor. In addition to being annoying, recurrent and persistent itching is expensive to treat. Kaposi varicelliform eruption, which is connected to a previous herpes infection, is a well-known side effect of AD.
Vesicular lesions first appear in the eczematous spot and can spread fast to healthy skin. Acyclovir therapy may help reduce morbidity. Staphylococcus and streptococcus skin infections are another risk factor for AD patients. Atopic dermatitis comes with a heavy mental burden in addition to its physical symptoms. It has been discovered that people with atopic dermatitis have a much lower quality of life as well as self-esteem, as well as more frequent sleep problems, and anxiety.
R&D spending has increased in the pharmaceutical and biopharmaceutical industries. The market for drug discovery services is seeing new, lucrative prospects arise as a result of the necessity for outsourcing analytical testing services, initiatives for research & development on atopic dermatitis medications, and the high cost of in-house drug development. A major driver of market expansion is the quick uptake of new technologies in the drug development process. The expansion of the market is, however, being constrained by issues including animal testing and medicinal research and development.
The Brazil market dominated the LAMEA Atopic Dermatitis Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $313.4 million by 2028.The Argentina market is poised to grow at a CAGR of 12% during (2022 - 2028). Additionally, The UAE market would witness a CAGR of 11.1% during (2022 - 2028).
Based on Route of Administration, the market is segmented into Injectable, Oral and Topical. Based on Class, the market is segmented into Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Atopic Dermatitis Drugs Market is Predict to reach $22 Billion by 2028, at a CAGR of 9.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer Inc., Sanofi SA, AbbVie Inc., Galderma S.A., Eli Lilly and Company, Leo Pharma A/S, Regeneron Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and Incyte Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration
By Class
- Biologics
- Calcineurin Inhibitors
- Corticosteroids
- PDE4 Inhibitors
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Pfizer Inc.
- Sanofi SA
- AbbVie Inc.
- Galderma S.A.
- Eli Lilly and Company
- Leo Pharma A/S
- Regeneron Pharmaceuticals Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Novartis AG
- Incyte Corporation
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Atopic Dermatitis Drugs Market, by Route of Administration
1.4.2 LAMEA Atopic Dermatitis Drugs Market, by Class
1.4.3 LAMEA Atopic Dermatitis Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Acquisition and Mergers
3.2.2 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2018, Sep – 2022, Oct) Leading Players
Chapter 4. LAMEA Atopic Dermatitis Drugs Market by Route of Administration
4.1 LAMEA Injectable Market by Country
4.2 LAMEA Oral Market by Country
4.3 LAMEA Topical Market by Country
Chapter 5. LAMEA Atopic Dermatitis Drugs Market by Class
5.1 LAMEA Biologics Market by Country
5.2 LAMEA Calcineurin Inhibitors Market by Country
5.3 LAMEA Corticosteroids Market by Country
5.4 LAMEA PDE4 Inhibitors Market by Country
5.5 LAMEA Others Market by Country
Chapter 6. LAMEA Atopic Dermatitis Drugs Market by Country
6.1 Brazil Atopic Dermatitis Drugs Market
6.1.1 Brazil Atopic Dermatitis Drugs Market by Route of Administration
6.1.2 Brazil Atopic Dermatitis Drugs Market by Class
6.2 Argentina Atopic Dermatitis Drugs Market
6.2.1 Argentina Atopic Dermatitis Drugs Market by Route of Administration
6.2.2 Argentina Atopic Dermatitis Drugs Market by Class
6.3 UAE Atopic Dermatitis Drugs Market
6.3.1 UAE Atopic Dermatitis Drugs Market by Route of Administration
6.3.2 UAE Atopic Dermatitis Drugs Market by Class
6.4 Saudi Arabia Atopic Dermatitis Drugs Market
6.4.1 Saudi Arabia Atopic Dermatitis Drugs Market by Route of Administration
6.4.2 Saudi Arabia Atopic Dermatitis Drugs Market by Class
6.5 South Africa Atopic Dermatitis Drugs Market
6.5.1 South Africa Atopic Dermatitis Drugs Market by Route of Administration
6.5.2 South Africa Atopic Dermatitis Drugs Market by Class
6.6 Nigeria Atopic Dermatitis Drugs Market
6.6.1 Nigeria Atopic Dermatitis Drugs Market by Route of Administration
6.6.2 Nigeria Atopic Dermatitis Drugs Market by Class
6.7 Rest of LAMEA Atopic Dermatitis Drugs Market
6.7.1 Rest of LAMEA Atopic Dermatitis Drugs Market by Route of Administration
6.7.2 Rest of LAMEA Atopic Dermatitis Drugs Market by Class
Chapter 7. Company Profiles
7.1 Pfizer, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional & Segmental Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals and Trials:
7.1.5.2 Acquisition and Mergers:
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Sanofi S.A.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.3.5.2 Acquisition and Mergers:
7.4 LEO Pharma A/S
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.4.5.2 Acquisition and Mergers:
7.5 Incyte Corporation
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Research & Development Expenses
7.5.4 Recent strategies and developments:
7.5.4.1 Approvals and Trials:
7.5.4.2 Acquisition and Mergers:
7.6 AbbVie, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.6.5.2 Acquisition and Mergers:
7.7 Regeneron Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expense
7.8 Eli Lilly And Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 Otsuka Pharmaceutical Co., Ltd.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Approvals and Trials:
7.9.2.2 Acquisition and Mergers:
7.10. Galderma S.A.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Acquisition and Mergers:
TABLE 1 LAMEA Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 2 LAMEA Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 3 Acquisition and Mergers– Atopic Dermatitis Drugs Market
TABLE 4 Approvals and trials – Atopic Dermatitis Drugs Market
TABLE 5 LAMEA Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 6 LAMEA Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 7 LAMEA Injectable Market by Country, 2018 - 2021, USD Million
TABLE 8 LAMEA Injectable Market by Country, 2022 - 2028, USD Million
TABLE 9 LAMEA Oral Market by Country, 2018 - 2021, USD Million
TABLE 10 LAMEA Oral Market by Country, 2022 - 2028, USD Million
TABLE 11 LAMEA Topical Market by Country, 2018 - 2021, USD Million
TABLE 12 LAMEA Topical Market by Country, 2022 - 2028, USD Million
TABLE 13 LAMEA Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 14 LAMEA Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 15 LAMEA Biologics Market by Country, 2018 - 2021, USD Million
TABLE 16 LAMEA Biologics Market by Country, 2022 - 2028, USD Million
TABLE 17 LAMEA Calcineurin Inhibitors Market by Country, 2018 - 2021, USD Million
TABLE 18 LAMEA Calcineurin Inhibitors Market by Country, 2022 - 2028, USD Million
TABLE 19 LAMEA Corticosteroids Market by Country, 2018 - 2021, USD Million
TABLE 20 LAMEA Corticosteroids Market by Country, 2022 - 2028, USD Million
TABLE 21 LAMEA PDE4 Inhibitors Market by Country, 2018 - 2021, USD Million
TABLE 22 LAMEA PDE4 Inhibitors Market by Country, 2022 - 2028, USD Million
TABLE 23 LAMEA Others Market by Country, 2018 - 2021, USD Million
TABLE 24 LAMEA Others Market by Country, 2022 - 2028, USD Million
TABLE 25 LAMEA Atopic Dermatitis Drugs Market by Country, 2018 - 2021, USD Million
TABLE 26 LAMEA Atopic Dermatitis Drugs Market by Country, 2022 - 2028, USD Million
TABLE 27 Brazil Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 28 Brazil Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 29 Brazil Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 30 Brazil Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 31 Brazil Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 32 Brazil Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 33 Argentina Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 34 Argentina Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 35 Argentina Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 36 Argentina Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 37 Argentina Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 38 Argentina Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 39 UAE Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 40 UAE Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 41 UAE Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 42 UAE Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 43 UAE Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 44 UAE Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 45 Saudi Arabia Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 46 Saudi Arabia Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 47 Saudi Arabia Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 48 Saudi Arabia Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 49 Saudi Arabia Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 50 Saudi Arabia Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 51 South Africa Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 52 South Africa Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 53 South Africa Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 54 South Africa Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 55 South Africa Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 56 South Africa Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 57 Nigeria Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 58 Nigeria Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 59 Nigeria Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 60 Nigeria Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 61 Nigeria Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 62 Nigeria Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 63 Rest of LAMEA Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 64 Rest of LAMEA Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 65 Rest of LAMEA Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 66 Rest of LAMEA Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 67 Rest of LAMEA Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 68 Rest of LAMEA Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 69 Key Information – Pfizer, Inc.
TABLE 70 Key Information – Novartis AG
TABLE 71 Key Information – Sanofi S.A.
TABLE 72 key information – LEO Pharma A/S
TABLE 73 Key Information – INCYTE CORPORATION
TABLE 74 Key information – AbbVie, Inc.
TABLE 75 Key Information – Regeneron Pharmaceuticals, Inc.
TABLE 76 Key Information – Eli Lilly And Company
TABLE 77 key information – Otsuka Pharmaceutical Co., Ltd.
TABLE 78 Key Information – Galderma S.A.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Acquisitions and Mergers: 2018, SeP – 2022, Oct) Leading Players
FIG 5 Recent strategies and developments: Pfizer, Inc.
FIG 6 Recent strategies and developments: sanofi s.a.
FIG 7 Recent strategies and developments: leo pharma a/s